Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Type 2 Diabetes Drugs Can Skip Cardiovascular Outcome Trials, But Phase III Must Be Longer, Broader
Mar 09 2020
•
By
Sue Sutter
US FDA has outlined a new development paradigm for type 2 diabetes drugs. • Source: Shutterstock
More from Drug Safety
More from Pink Sheet